Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 open-label, dose-ranging Study of SIG002 of for the Treatment of Big Toe Osteoarthritis (Hallux Rigidus)

Next Previous
Search
Trial Profile

Phase 1 open-label, dose-ranging Study of SIG002 of for the Treatment of Big Toe Osteoarthritis (Hallux Rigidus)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SIG 002 Arugula Sciences (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Arugula Sciences

    • Most Recent Events

    • 03 Feb 2023 New trial record
    • 31 Jan 2023 According to a Arugula Sciences media release, the company has partnered with Dr. Matthew Negaard at the Forte Orthopedic Research Institute, a not-for-profit organization associated with the Forte Sports Medicine and Orthopedics clinic in Carmel, IN.
    • 31 Jan 2023 According to a Arugula Sciences media release, the company has received clearance from the FDA for an investigational new drug (IND) application to initiate this trial and first participant is expected to be enrolled in February 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top